CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)

$0 None (None%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 89

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) News Sources

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

15-04-2026

yahoo.com

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

14-04-2026

yahoo.com

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

07-04-2026

yahoo.com

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

07-04-2026

yahoo.com

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026

02-04-2026

yahoo.com

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

01-04-2026

yahoo.com

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

27-03-2026

yahoo.com

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

24-03-2026

yahoo.com

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

04-11-2025

yahoo.com

Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND

03-11-2025

yahoo.com

CLDWW stock
CLDWW stock price
CLDWW stock price today
CLDWW stock prediction
CLDWW earnings date
CLDWW news
CLDWW price
CLDWW share
CLDWW share price
CLDWW shares
CLDWW ceo
CLDWW premarket
$CLDWW
CLDWW ticker
CLDWW after hours
CLDWW stock
CLDWW stock price
CLDWW stock price today
CLDWW stock prediction
CLDWW earnings date
CLDWW news
CLDWW price
CLDWW share
CLDWW share price
CLDWW shares
CLDWW ceo
CLDWW premarket
$CLDWW
CLDWW ticker
CLDWW after hours

CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) Sentiment Trend

View FAQ

CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) FAQs

toggle

What is the current price of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?

The current price of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is $0.


toggle

CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) absolute price change since previous trading day?

The absolute price change of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) since the previous trading day is $None.


toggle

CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) percentage price change since previous trading day?

The percentage price change of CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) since the previous trading day is None%.


toggle

What is the most recent average sentiment score for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?

The most recent average sentiment score for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is 89 out of 100.


toggle

What is the most recent average sentiment for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)?

The most recent sentiment for CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS) is .


SEC-8K** Filing Available For CALIDI BIOTHERAPEUTICS -CW23 (CLDWW:OTCMKTS)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.